Ayala Pharmaceuticals Inc (AYLA)

[crudeoil24]

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Ayala Pharmaceuticals (AYLA – Research Report) today and set a price target of $12.00. The company's shares closed last Tuesday at $1.69, close to its 52-week low of $0.70. According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 8.9% and a 33.6% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Onconova Therapeutics, and PDS Biotechnology. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ayala Pharmaceuticals with a $15.00 average price target.
https://www.tipranks.com/news/blurbs/noble-financial-thinks-ayala-pharmaceuticals-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral